NCT06860334View on ClinicalTrials.gov

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

378

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

August 31, 2028

Conditions

Crimean-Congo Hemorrhagic Fever

Interventions

DRUG

Favipiravir

6-fluoro-3-hydroxypyrazine-2-carboxamide, T-705

DRUG

Ribavin

1-3,4-dihydroxy-5-1,2,4-triazole-3-carboxamide

OTHER

Optimised Standard of Care

Optimised standard of care will include treatment per national guidelines for CCHF case management in Turkiye and Iraq, and any other supportive medication or therapies as required.

All Listed Sponsors

lead

Liverpool School of Tropical Medicine

OTHER